BioCentury | Nov 5, 2012
Company News

Agenix, Tyrian deal

...to Tyrian's DianostIQ rapid point-of-care technology for human health applications. As part of the deal, Agenix...
...tuberculosis infection and previous infection or vaccination. Tyrian will receive Agenix shares totaling A$500,000 ($517,251). Agenix...
...to develop the technology into a single microarray device that will process multiple diagnostic tests. Agenix Ltd....
BioCentury | Jul 9, 2012
Company News

Agenix management update

Agenix Ltd. (ASX:AGX), Melbourne, Australia Business: Infectious, Diagnostic Hired: Paul Resnick as senior business advisor, formerly VP of business development at Intellikine Inc. , which Takeda Pharmaceuticals Co. Ltd. acquired WIR Staff...
BioCentury | Oct 24, 2011
Company News

Agenix, Chinese Academy of Medical Sciences, Chinese Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences deal

...candidates to treat cancer and infectious diseases and share IP, production, marketing and distribution rights. Agenix...
...regulatory expertise. The partners will work together in any licensing discussions with third parties. Separately, Agenix's...
...subsidiary partnered with the institute to complete final toxicology tests for HBV candidate AGX-1009 . Agenix...
BioCentury | Aug 15, 2005
Company News

Agenix, Akzo Nobel NV deal

...as an imaging agent to detect blood clots in patients with deep vein thrombosis (DVT). Agenix Ltd....
BioCentury | May 16, 2005
Finance

Taking the ADR route

...BNY 9/5/02 sanofi-aventis NYSE SNY France BNY 7/1/02 Guangzhou Pharmaceutical OTC GZPHY China BNY 6/21/02 Agenix...
BioCentury | Dec 8, 2003
Company News

Agenix, Biosite deal

Agenix Ltd. (ASX:AGX; AGXLY), Brisbane, Australia Biosite Inc. (BSTE), San Diego, Calif. Business: Diagnostic The companies will incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage Profiler S.O.B. Panel to identify causes of shortness of...
BioCentury | Nov 26, 2003
Company News

Agenix, Biosite diagnostic deal

...BSTE partnered with Agenix (ASX:AGX; AGXLY) to incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage...
BioCentury | Sep 22, 2003
Clinical News

ThromboView: Phase Ib

...dose level. AGX said it would increase the dose in the next group of patients. Agenix Ltd....
BioCentury | Jul 14, 2003
Clinical News

ThromboView: Phase Ib

...Australian Phase Ib trial in 32 patients, ThromboView detected deep vein thrombosis in 1 patient. Agenix Ltd....
BioCentury | Jul 14, 2003
Clinical News

ThromboView: Phase Ia

...In an open-label Australian Phase Ia trial in 32 healthy volunteers, ThromboView was well tolerated. Agenix Ltd....
Items per page:
1 - 10 of 13
BioCentury | Nov 5, 2012
Company News

Agenix, Tyrian deal

...to Tyrian's DianostIQ rapid point-of-care technology for human health applications. As part of the deal, Agenix...
...tuberculosis infection and previous infection or vaccination. Tyrian will receive Agenix shares totaling A$500,000 ($517,251). Agenix...
...to develop the technology into a single microarray device that will process multiple diagnostic tests. Agenix Ltd....
BioCentury | Jul 9, 2012
Company News

Agenix management update

Agenix Ltd. (ASX:AGX), Melbourne, Australia Business: Infectious, Diagnostic Hired: Paul Resnick as senior business advisor, formerly VP of business development at Intellikine Inc. , which Takeda Pharmaceuticals Co. Ltd. acquired WIR Staff...
BioCentury | Oct 24, 2011
Company News

Agenix, Chinese Academy of Medical Sciences, Chinese Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences deal

...candidates to treat cancer and infectious diseases and share IP, production, marketing and distribution rights. Agenix...
...regulatory expertise. The partners will work together in any licensing discussions with third parties. Separately, Agenix's...
...subsidiary partnered with the institute to complete final toxicology tests for HBV candidate AGX-1009 . Agenix...
BioCentury | Aug 15, 2005
Company News

Agenix, Akzo Nobel NV deal

...as an imaging agent to detect blood clots in patients with deep vein thrombosis (DVT). Agenix Ltd....
BioCentury | May 16, 2005
Finance

Taking the ADR route

...BNY 9/5/02 sanofi-aventis NYSE SNY France BNY 7/1/02 Guangzhou Pharmaceutical OTC GZPHY China BNY 6/21/02 Agenix...
BioCentury | Dec 8, 2003
Company News

Agenix, Biosite deal

Agenix Ltd. (ASX:AGX; AGXLY), Brisbane, Australia Biosite Inc. (BSTE), San Diego, Calif. Business: Diagnostic The companies will incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage Profiler S.O.B. Panel to identify causes of shortness of...
BioCentury | Nov 26, 2003
Company News

Agenix, Biosite diagnostic deal

...BSTE partnered with Agenix (ASX:AGX; AGXLY) to incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage...
BioCentury | Sep 22, 2003
Clinical News

ThromboView: Phase Ib

...dose level. AGX said it would increase the dose in the next group of patients. Agenix Ltd....
BioCentury | Jul 14, 2003
Clinical News

ThromboView: Phase Ib

...Australian Phase Ib trial in 32 patients, ThromboView detected deep vein thrombosis in 1 patient. Agenix Ltd....
BioCentury | Jul 14, 2003
Clinical News

ThromboView: Phase Ia

...In an open-label Australian Phase Ia trial in 32 healthy volunteers, ThromboView was well tolerated. Agenix Ltd....
Items per page:
1 - 10 of 13